Globus Medical Q3 net sales $254.1M (+10.6% YoY); lowers FY22 non-GAAP EPS guidance to $2.03

GLOBUS MEDICAL INC

2022-Q3 EPS reported $1.36 revenue$748,345,000

Q3 net sales $254.1M, up 10.6% as-reported and 12.6% constant currency; GAAP net income $47.4M, +0.5% YoY.
GAAP diluted EPS $0.47, non-GAAP diluted EPS $0.50; non-GAAP adjusted EBITDA $82.8M (32.6% of sales).
U.S. Spine sales +9.0%, International Spine +11.1% as-reported (+24.8% constant currency); Enabling Technologies +19.0% to $24.1M.
FY 2022 net sales reaffirmed at $1.025B; non-GAAP diluted EPS guidance lowered to $2.03 from $2.10 due to currency and tax.
Company remains debt-free; operating cash flow $32.9M and free cash flow $20.9M in Q3.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GLOBUS MEDICAL INC reported quarter ended September 30, 2022 results: revenue $254.1 million, net income $47.4 million, EPS $0.47. Guidance reaffirmed.

Period: quarter ended September 30, 2022
Revenue: $254.1 million
Net income: $47.4 million
EPS: $0.47
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2022 . · Worldwide net sales were $254.1 million , an increase of 10.6% , or 12.6% on a constant currency basis · GAAP net income for the quarter was $47.4 million · GAAP d iluted earnings per share (“ EPS ”) was $0.47 and

View on SEC.gov

Browse all earnings releases →

GLOBUS MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001562762-22-000444

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.